2023
Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis
Mooring M, Yeung G, Luukkonen P, Liu S, Akbar M, Zhang G, Balogun O, Yu X, Mo R, Nejak-Bowen K, Poyurovsky M, Booth C, Konnikova L, Shulman G, Yimlamai D. Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis. Science Translational Medicine 2023, 15: eade3157. PMID: 37756381, PMCID: PMC10874639, DOI: 10.1126/scitranslmed.ade3157.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisLiver inflammationNonalcoholic fatty liver diseaseProgression of NASHCysteine-rich angiogenic inducer 61Fatty liver diseaseLiver-specific knockout miceImproved glucose toleranceType 2 diabetesGlucose toleranceLiver diseaseNASH progressionProfibrotic macrophagesProinflammatory propertiesReduced fibrosisCardiovascular diseaseProfibrotic phenotypeFibrotic developmentKnockout miceNF-κBMetabolic diseasesNASH dietPDGFB expressionFibrosisProfibrotic program
2009
Evaluation of hepatic fibrosis with portal pressure gradient in rats
Wang Y, Booth CJ, Kim H, Qiu M, Constable RT. Evaluation of hepatic fibrosis with portal pressure gradient in rats. Magnetic Resonance In Medicine 2009, 61: 1185-1192. PMID: 19253377, PMCID: PMC11210607, DOI: 10.1002/mrm.21964.Peer-Reviewed Original ResearchConceptsHepatic fibrosisFibrosis scorePortal pressure gradientCirrhosis groupFibrosis groupLiver fibrosisLiver pathologyPortal veinHistological examinationAnimal studiesNoninvasive assessmentFibrosisNoninvasive meansGradient echo sequenceVessel areaSignificant differencesRatsContrast agentsEcho sequenceScoresCarbon tetrachlorideGroupPhantom study